163 related articles for article (PubMed ID: 18666714)
1. Behavioral and biochemical effects of amperozide and serotonin agents on nigrostriatal and mesolimbic dopamine systems.
Chang PY; Chuang CH; Chen JC; Tung CS
Chin J Physiol; 2008 Apr; 51(2):106-15. PubMed ID: 18666714
[TBL] [Abstract][Full Text] [Related]
2. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
3. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action.
Meltzer HY; Zhang Y; Stockmeier CA
Eur J Pharmacol; 1992 May; 216(1):67-71. PubMed ID: 1388121
[TBL] [Abstract][Full Text] [Related]
4. Amperozide--a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour.
Gustafsson B; Christensson E
Pharmacol Toxicol; 1990; 66 Suppl 1():12-7. PubMed ID: 1968250
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute administration of SCH 23390 on dopamine and serotonin turnover in major dopaminergic areas and mesencephalic raphe nuclei--comparison with ritanserin.
Lappalainen J; Hietala J; Koulu M; Sjöholm B; Syvälahti E
Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(6):861-72. PubMed ID: 1722342
[TBL] [Abstract][Full Text] [Related]
6. The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding.
Svartengren J; Celander M
Eur J Pharmacol; 1994 Mar; 254(1-2):73-81. PubMed ID: 7911431
[TBL] [Abstract][Full Text] [Related]
7. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux.
Pehek EA; Meltzer HY; Yamamoto BK
Eur J Pharmacol; 1993 Aug; 240(1):107-9. PubMed ID: 8405119
[TBL] [Abstract][Full Text] [Related]
8. The effect of amperozide on uptake and release of [3H]-dopamine in vitro from perfused rat striatal and limbic brain areas.
Eriksson E; Christensson E
Pharmacol Toxicol; 1990; 66 Suppl 1():45-8. PubMed ID: 2304895
[TBL] [Abstract][Full Text] [Related]
9. Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens.
Ichikawa J; Meltzer HY
J Neurochem; 1992 Jun; 58(6):2285-91. PubMed ID: 1349347
[TBL] [Abstract][Full Text] [Related]
10. The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo.
Yamamoto BK; Meltzer HY
J Pharmacol Exp Ther; 1992 Oct; 263(1):180-5. PubMed ID: 1403783
[TBL] [Abstract][Full Text] [Related]
11. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release.
Broderick PA; Piercey MF
J Neural Transm (Vienna); 1998; 105(6-7):749-67. PubMed ID: 9826116
[TBL] [Abstract][Full Text] [Related]
12. The effect of amperozide, a new antipsychotic drug, on plasma corticosterone concentration in the rat.
Albinsson A; Andersson G
Life Sci; 1992; 51(19):1535-44. PubMed ID: 1359366
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the 5-HT2 receptor in the 5-HT receptor-mediated stimulation of prolactin release.
Albinsson A; Palazidou E; Stephenson J; Andersson G
Eur J Pharmacol; 1994 Jan; 251(2-3):157-61. PubMed ID: 8149973
[TBL] [Abstract][Full Text] [Related]
14. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Kitaichi K; Yamada K; Hasegawa T; Furukawa H; Nabeshima T
Jpn J Pharmacol; 1994 Oct; 66(2):181-9. PubMed ID: 7532732
[TBL] [Abstract][Full Text] [Related]
15. The putatively antipsychotic agent amperozide produces behavioural stimulation in the rat. A behavioural and biochemical characterization.
Waters N; Pettersson G; Carlsson A; Svensson K
Naunyn Schmiedebergs Arch Pharmacol; 1989 Aug; 340(2):161-9. PubMed ID: 2572972
[TBL] [Abstract][Full Text] [Related]
16. Amperozide, a 5-HT2 antagonist, attenuates craving for cocaine by rats.
McMillen BA; Jones EA; Hill LJ; Williams HL; Björk A; Myers RD
Pharmacol Biochem Behav; 1993 Sep; 46(1):125-9. PubMed ID: 8255902
[TBL] [Abstract][Full Text] [Related]
17. Effects of B-HT 920 on nigrostriatal and mesolimbic dopamine systems in normosensitive and supersensitive rats.
Clarke PB; Wyder KJ; Jakubovic A; Fibiger HC
Br J Pharmacol; 1990 Mar; 99(3):509-15. PubMed ID: 2110017
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study.
Di Giovanni G; De Deurwaerdére P; Di Mascio M; Di Matteo V; Esposito E; Spampinato U
Neuroscience; 1999; 91(2):587-97. PubMed ID: 10366016
[TBL] [Abstract][Full Text] [Related]
19. In vivo electrochemical and behavioral evidence for specific neural substrates modulated differentially by enkephalin in rat stimulant stereotypy and locomotion.
Broderick PA; Gardner EL; van Praag HM
Biol Psychiatry; 1984 Jan; 19(1):45-54. PubMed ID: 6538442
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex.
Nomikos GG; Iurlo M; Andersson JL; Kimura K; Svensson TH
Psychopharmacology (Berl); 1994 Jun; 115(1-2):147-56. PubMed ID: 7862887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
